Tetherex Pharmaceuticals Corporation   Report issue

For profit Phase 1 Phase 2
Founded: Oklahoma City OK United States (2014)

Organization Overview

First Clinical Trial
2019
NCT03812328
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Tetherex Pharmaceuticals Corporation

Active Ingredients

Drugs in Phase 2 Trials (2)

enoxaparin (lovenox) (1 trial)

selk2 (2 trials)

Drugs in Phase 1 Trials (1)

sc-ad6-1 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Thromboembolism (Phase 2)

Venous Thromboembolism (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3